EU SPC Waiver Move Puts Originator And Generic/Biosimilar Firms At Odds

 
• By Ian Schofield
  
Intellectual Property law books and a gavel on desk in the library. concept of legal education.
A planned change to EU IP laws would allow generic/biosimilar production during the SPC period, but for export only.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Legal & IP

More from Pink Sheet